In just two weeks, European life science companies have tapped the global capital markets for more than $900 million, taking advantage of buoyant stock prices and a favourable global economy. Funds have been raised by clinical stage companies developing medical therapeutics and devices, as well as by one venture capital company, BioGeneration Ventures. BioGeneration specialises in seed funding for European start-ups.
Full text available to subscribers only. Click here for information on subscribing to MedNous.